Beraprost-d3

Beraprost-d3 (TRK-100-d3) is deuterium labeled (Rac) -Beraprost. (Rac) -Beraprost ((Rac) -ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis[1].

Product Specifications

Product Name Alternative

TRK-100-d3; ML 1129-d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Prostaglandin Receptor

Related Pathways

GPCR/G Protein; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C(CCCC1=CC=CC2=C1OC3CC(C(C23)/C=C/C(C(CC#CC)C([2H])([2H])[2H])O)O)O

Molecular Formula

C24H27D3O5

Molecular Weight

401.51

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Li S, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl) . 2019 Jun;97 (6) :777-791.